Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 2
1990 2
1991 3
1992 6
1993 2
1994 6
1995 11
1996 14
1997 7
1998 13
1999 16
2000 16
2001 11
2002 15
2003 20
2004 30
2005 33
2006 35
2007 42
2008 51
2009 39
2010 35
2011 51
2012 40
2013 73
2014 110
2015 141
2016 147
2017 148
2018 158
2019 186
2020 223
2021 171
Text availability
Article attribute
Article type
Publication date

Search Results

1,630 results
Results by year
Filters applied: . Clear all
Page 1
Atrial Fibrillation: JACC Council Perspectives.
Chung MK, Refaat M, Shen WK, Kutyifa V, Cha YM, Di Biase L, Baranchuk A, Lampert R, Natale A, Fisher J, Lakkireddy DR; ACC Electrophysiology Section Leadership Council. Chung MK, et al. J Am Coll Cardiol. 2020 Apr 14;75(14):1689-1713. doi: 10.1016/j.jacc.2020.02.025. J Am Coll Cardiol. 2020. PMID: 32273035 Free article. Review.
Atrial fibrillation (AF) is an increasingly prevalent arrhythmia; its pathophysiology and progression are well studied. ...
Atrial fibrillation (AF) is an increasingly prevalent arrhythmia; its pathophysiology and progression are well studied. ...
Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY. Holmes DR Jr, et al. J Am Coll Cardiol. 2014 Jul 8;64(1):1-12. doi: 10.1016/j.jacc.2014.04.029. J Am Coll Cardiol. 2014. PMID: 24998121 Free article. Clinical Trial.
BACKGROUND: In the PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation) trial that evaluated patients with nonvalvular atrial fibrillation (NVAF), left atrial appendage …
BACKGROUND: In the PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial
5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, Horton RP, Buchbinder M, Neuzil P, Gordon NT, Holmes DR Jr; PREVAIL and PROTECT AF Investigators. Reddy VY, et al. J Am Coll Cardiol. 2017 Dec 19;70(24):2964-2975. doi: 10.1016/j.jacc.2017.10.021. Epub 2017 Nov 4. J Am Coll Cardiol. 2017. PMID: 29103847 Free article. Clinical Trial.
BACKGROUND: The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific, St. ...(WATCHMAN Le …
BACKGROUND: The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillati
Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial.
Poole JE, Bahnson TD, Monahan KH, Johnson G, Rostami H, Silverstein AP, Al-Khalidi HR, Rosenberg Y, Mark DB, Lee KL, Packer DL; CABANA Investigators and ECG Rhythm Core Lab. Poole JE, et al. J Am Coll Cardiol. 2020 Jun 30;75(25):3105-3118. doi: 10.1016/j.jacc.2020.04.065. J Am Coll Cardiol. 2020. PMID: 32586583 Free PMC article. Clinical Trial.
BACKGROUND: The CABANA (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial randomized 2,204 patients with atrial fibrillation (AF) to catheter ablation or drug therapy. ...Furthermore, AF burden was also significantly r …
BACKGROUND: The CABANA (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial randomized 2,204 p …
Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment: A Review.
Linz D, McEvoy RD, Cowie MR, Somers VK, Nattel S, Lévy P, Kalman JM, Sanders P. Linz D, et al. JAMA Cardiol. 2018 Jun 1;3(6):532-540. doi: 10.1001/jamacardio.2018.0095. JAMA Cardiol. 2018. PMID: 29541763 Free article. Review.
IMPORTANCE: Obstructive sleep apnea (OSA) is the most common clinically significant breathing abnormality during sleep. It is highly prevalent among patients with atrial fibrillation (AF), and it promotes arrhythmogenesis and impairs treatment efficacy. ...Because t …
IMPORTANCE: Obstructive sleep apnea (OSA) is the most common clinically significant breathing abnormality during sleep. It is highly prevale …
Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.
Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, Daniels MR, Bahnson TD, Poole JE, Rosenberg Y, Lee KL, Packer DL; CABANA Investigators. Mark DB, et al. JAMA. 2019 Apr 2;321(13):1275-1285. doi: 10.1001/jama.2019.0692. JAMA. 2019. PMID: 30874716 Free PMC article. Clinical Trial.
IMPORTANCE: Catheter ablation is more effective than drug therapy in restoring sinus rhythm in patients with atrial fibrillation (AF), but its incremental effect on long-term quality of life (QOL) is uncertain. ...These findings can help guide decisions regarding ma …
IMPORTANCE: Catheter ablation is more effective than drug therapy in restoring sinus rhythm in patients with atrial fibrillation
Cognitive dysfunction in atrial fibrillation.
Madhavan M, Graff-Radford J, Piccini JP, Gersh BJ. Madhavan M, et al. Nat Rev Cardiol. 2018 Dec;15(12):744-756. doi: 10.1038/s41569-018-0075-z. Nat Rev Cardiol. 2018. PMID: 30275499 Review.
Atrial fibrillation (AF) is the most common arrhythmia in adults, and its incidence and prevalence increase with age. ...
Atrial fibrillation (AF) is the most common arrhythmia in adults, and its incidence and prevalence increase with age. ...
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH. Avezum A, et al. Circulation. 2015 Aug 25;132(8):624-32. doi: 10.1161/CIRCULATIONAHA.114.014807. Epub 2015 Jun 23. Circulation. 2015. PMID: 26106009 Clinical Trial.
BACKGROUND: Apixaban is approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. However, the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial …
BACKGROUND: Apixaban is approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillati
Ischemic Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: JACC Review Topic of the Week.
Alkhouli M, Friedman PA. Alkhouli M, et al. J Am Coll Cardiol. 2019 Dec 17;74(24):3050-3065. doi: 10.1016/j.jacc.2019.10.040. Epub 2019 Dec 9. J Am Coll Cardiol. 2019. PMID: 31865973 Free article. Review.
The last decade has witnessed remarkable advances in pharmacological and nonpharmacological strategies for stroke prevention in patients with atrial fibrillation. However, the currently available clinical stroke risk prediction models do not account for key nonclini …
The last decade has witnessed remarkable advances in pharmacological and nonpharmacological strategies for stroke prevention in patients wit …
1,630 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page